Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Genscript Biotech Crp Ord (OP:GNNSF)

1.550 -0.220 (-12.43%)
Streaming Delayed Price Updated: 9:56 AM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Genscript Biotech Crp Ord

News headline image
Will Genscript Cash Out Of Legend Biotech In The Face Of Fat Profit Temptation? ↗
Key Takeaways: Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its... 
Via Benzinga
News headline image
Week In Review: Korea's SK Biopharma Acquires Radiopharmaceutical In $571 Million Deal ↗
In recent news, South Korea’s SK Biopharma in-licensed global rights to a radiopharmaceutical compound developed by Full-Life Technologies of Shanghai in a $571 million deal. 
Via Talk Markets
News headline image
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million ↗
Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent... 
Via Talk Markets
News headline image
3 DNA Stocks to Buy for the Synthetic Biology Revolution ↗
Synthetic biology is a growing industry. The big winners will be DNA stocks that are able to sell to everyone, not just a small niche. 
Via InvestorPlace
News headline image
The Next Big Disruptors? 3 Biotech Stocks Making Headlines. ↗
Biotech stocks were hard-hit in 2022, but these disruptive names in the field of synthetic biology can be big winners in 2023. 
Via InvestorPlace
News headline image
Week In Review: Mabwell Out-Licenses Rare Disease Drug For $412.5 Million ↗
Mabwell Biosciences out-licensed global rights for a rare disease drug to Disc Medicine of Cambridge, MA in a $412.5 million agreement. Mabwell will receive $10 million upfront, $402.5 million in... 
Via Talk Markets
News headline image
Three Pharma Stocks to Sell Before They Die ↗
As we head into New Year 2023, these are just some of the top pharma stocks to sell at the start of January. 
Via InvestorPlace
News headline image
Week In Review: Akeso Out-Licenses PD-1/VEGF To Summit In $5 Billion Pact ↗
In a blockbuster agreement, Guangzhou’s Akeso out-licensed ex-China rights to its bispecific PD-1/VEGF candidate in a deal worth up to $5 billion. Summit Therapeutics will pay $500 million upfront and... 
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.